Cargando…

Management of Combined Therapy (Ceritinib, A. cinnamomea, G. lucidum, and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report

The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Chuan-Tsung, Wu, Jih-Huah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228003/ https://www.ncbi.nlm.nih.gov/pubmed/35743893 http://dx.doi.org/10.3390/life12060862

Ejemplares similares

Dose Analysis of Photobiomodulation Therapy in Stomatology
por: Su, Chuan-Tsung, et al.
Publicado: (2020)

A System Based on Photoplethysmography and Photobiomodulation for Autonomic Nervous System Measurement and Adjustment
por: Shan, Yi-Chia, et al.
Publicado: (2023)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer
por: Schaefer, Eric S, et al.
Publicado: (2016)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Antrodia Cinnamomea Prolongs Survival in a Patient with Small Cell Lung Cancer
por: Long, Huei, et al.
Publicado: (2019)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

The Versatile Functions of G. Lucidum Polysaccharides and G. Lucidum Triterpenes in Cancer Radiotherapy and Chemotherapy
por: Xu, Jing, et al.
Publicado: (2021)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
por: Lee, Mi-Sook, et al.
Publicado: (2020)

Antrodia cinnamomea induces anti-tumor activity by inhibiting the STAT3 signaling pathway in lung cancer cells
por: Huang, Tsung-Teng, et al.
Publicado: (2019)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Metabolomic Profiling of Different Antrodia cinnamomea Phenotypes
por: Su, Chun-Han, et al.
Publicado: (2023)

Anti-cachectic effect of Antrodia cinnamomea extract in lung tumor-bearing mice under chemotherapy
por: Chen, Meng-Chuan, et al.
Publicado: (2018)

MicroRNA-Like Small RNAs Prediction in the Development of Antrodia cinnamomea
por: Lin, Yan-Liang, et al.
Publicado: (2015)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer
por: Tsai, Ming-Yen, et al.
Publicado: (2016)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Genotoxic, teratotoxic and oral toxic assessments of Antrodia cinnamomea health food product (Leader Deluxe Antrodia cinnamomea(®))
por: Lin, Chin-Chung, et al.
Publicado: (2015)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
por: Li, Hui, et al.
Publicado: (2022)

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
por: Liao, Juanyan, et al.
Publicado: (2022)

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
por: Nishio, Makoto, et al.
Publicado: (2015)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2021)

Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
por: Mai, Shixiong, et al.
Publicado: (2022)

Topical Application of Antrodia cinnamomea Ointment in Diabetic Wound Healing
por: Su, Ruey-Chih, et al.
Publicado: (2022)

In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Du, Ping, et al.
Publicado: (2020)

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
por: Zhu, Zhouyu, et al.
Publicado: (2017)

Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report
por: Lim, Sun M., et al.
Publicado: (2018)

Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis
por: Tian, Wei, et al.
Publicado: (2020)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
por: Hoang, Tung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqepug0l5aqjv87u8dm5d4bft1